🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Muscle Growth3 cited studies

Ipamorelin

Selective growth hormone secretagogue with minimal cortisol or prolactin impact.

SummaryMechanismDosingSafetyStudies
Research use only — not for human consumption.

What it is

Ipamorelin is a pentapeptide ghrelin-receptor agonist that selectively stimulates GH release without significantly affecting cortisol, prolactin, or other pituitary hormones. By promoting natural GH pulses, it can support recovery from exercise and injury, lean body composition over time, and deeper sleep — making it a popular choice in performance and wellness protocols for its clean profile.

Mechanism of action

Agonist at the growth hormone secretagogue receptor (GHSR-1a / ghrelin receptor) on pituitary and hypothalamic neurons. Unlike older secretagogues (GHRP-2, GHRP-6), ipamorelin has minimal appetite or cortisol effects.

Half-life: ~2 hours.

Evidence summary

The original Raun 1998 paper established its selectivity. Pharmacokinetic-pharmacodynamic and Phase 2 work has explored post-operative ileus and GH response in healthy volunteers. No long-term GH-replacement data available.

Pantheon dosing guide

Application
Subcutaneous injection.
BAC Water
2 mg: 2 ml 5 mg: 2.5 ml
Dose
2 mg: 10 units (100 mcg) to 20 units (200 mcg). 5 mg: 10 units (200 mcg).
Frequency & Cycle Length
5 days on / 2 off. 4 to 5 weeks.
Timing
Before bedtime on an empty stomach.
Key Benefits
Stimulates natural growth hormone release. Enhances recovery and tissue repair. Increases lean muscle mass. Promotes fat loss. Improves sleep quality.

Additional research protocol context

The printed guide above is Pantheon's dosing reference. These broader research examples are provided as context and may use different schedules.

  • 200–300 mcg subcutaneous, 1–3 times daily
  • Best timed before bed (amplifies nocturnal GH pulse) or post-workout
  • 12-week cycles, often stacked with CJC-1295

Side effects & safety

  • Mild injection-site irritation
  • Rare head-rush or transient tiredness
  • Generally considered one of the cleanest GH secretagogues

Cited studies

  1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.
    PMID 9728535Read source ↗
  2. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Healthy Volunteers. Pharmaceutical Research.
    Read source ↗
  3. (2014). Prospective, Randomized, Controlled Study of Ipamorelin for Post-Operative Ileus. International Journal of Colorectal Disease.
    Read source ↗
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.